Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

To assess depression response and remission rates with electroconvulsive therapy (ECT) in a community clinic and to identify factors predicting success in treatment. Thirty-five patients were identified by a retrospective chart review with a diagnosis of major depressive disorder or depressive disorder not otherwise specified (according to the ) who were treated with an acute series of ECT at a community ECT clinic from March 1, 2014, to March 9, 2015. Logistic regression examined associations between clinical variables and depression response (defined as ≥50% reduction in score on the Patient Health Questionnaire-9 [PHQ-9]) and remission (final PHQ-9 score <5) rates and anxiety response rates (based on the Generalized Anxiety Disorder 7 item). Depression response and remission rates were 54.3% and 31.4%, respectively. This was a highly treatment-resistant sample, with an average of 5.3 antidepressant trials prior to initiating ECT. Improvement in anxiety symptoms was associated with depression response (odds ratio: 1.41, 95% CI, 1.11-1.78). Additionally, patients with initial severe anxiety scores were less likely than other patients to exhibit a response in depression (=.027). Almost half of this sample of patients with treatment-resistant depression did not respond to ECT in this community-based clinic, highlighting the challenges of treating this condition. Comorbid anxiety symptoms may reduce the likelihood of depression response, as patients with severe anxiety were less likely to respond. .

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.25m03939DOI Listing

Publication Analysis

Top Keywords

depression response
12
electroconvulsive therapy
8
ect community
8
depressive disorder
8
response
5
depression
4
depression remission
4
remission response
4
response rates
4
rates anxiety
4

Similar Publications

Unlabelled: Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological properties, such as N-methyl-D-aspartate (NMDA) receptor antagonism and anti-inflammatory effects. The potential of ketamine in treating depression has sparked debate regarding its effects on appetite.

View Article and Find Full Text PDF

Firefighters often serve as emergency medical services providers and face repeated exposure to potentially traumatic events (PTEs) while participating in opioid overdose responses (OORs), which may impact their mental health. A survey of 173 firefighters who had participated in an OOR in the previous 6 months was used to assess exposure to PTEs during such events, job stress, mental health symptoms, and resources used to address mental health symptoms. Most firefighters (97%) reported experiencing one or more PTEs while responding to an opioid overdose in the past 6 months.

View Article and Find Full Text PDF

Introduction: Anxiety, depression, and insomnia are common among older patients with tuberculosis (TB), yet their associations with inflammatory responses and drug-induced liver injury (DILI) remain insufficiently explored. This study aimed to identify distinct inflammation-DILI phenotypes in older TB patients and examine differences in anxiety, depression, and insomnia across subgroups.

Methods: In this cross-sectional study, 251 older TB patients were evaluated.

View Article and Find Full Text PDF

Background Breast augmentation surgery (BAS) is one of the top cosmetic surgical procedures performed in the United States every year. There are various breast implant options, such as saline, silicone, smooth, and textured implants. Breast implant illness (BII) is a disorder associated with a wide array of symptoms presenting post breast implant surgery and is often associated with autoimmune disorders.

View Article and Find Full Text PDF

Background: Herein, we report on the initial development, progress, and future plans for an autonomous artificial intelligence (AI) system designed to manage major depressive disorder (MDD). The system is a web-based, patient-facing conversational AI that collects medical history, provides presumed diagnosis, recommends treatment, and coordinates care for patients with MDD.

Methods: The system includes seven components, five of which are complete and two are in development.

View Article and Find Full Text PDF